Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Public ClinicalTrials.gov record NCT02365766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Study identification
- NCT ID
- NCT02365766
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Jason R. Brown
- Other
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- Gemcitabine Drug
- Cisplatin Drug
- Consolidative Surgery Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2015
- Primary completion
- Jul 31, 2020
- Completion
- Feb 22, 2024
- Last update posted
- Mar 17, 2025
2015 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| IU Health Central Indiana Cancer Center | Indianapolis | Indiana | 46219 | — |
| Community Regional Cancer Care | Indianapolis | Indiana | 46256 | — |
| St. Vincent Hospital | Indianapolis | Indiana | 46260 | — |
| Washington University: Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87106 | — |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Thomas Jefferson University: Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02365766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02365766 live on ClinicalTrials.gov.